Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis

Minoru Satoh, Jason Y F Chan, Steven J. Ross, Yi Li, Yoshioki Yamasaki, Hidehiro Yamada, Monica V Del Mercado, Marcelo H. Petri, Luis J. Jara, Miguel A. Saavedra, Claudia Cruz-Reyes, Eric S. Sobel, Westley H. Reeves, Angela Ceribelli, Edward K L Chan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction: Myositis specific autoantibodies are associated with unique clinical subsets and are useful biomarkers in polymyositis/dermatomyositis (PM/DM). A 120 kD protein recognized by certain patients with DM was identified and clinical features of patients with this specificity were characterized.Methods: The 120 kD protein recognized by a prototype serum was purified and identified by mass spectrometry and immunological methods. Autoantibody to this 120 kD protein was screened in sera from 2,356 patients with various diagnoses from four countries, including 254 PM/DM, by immunoprecipitation of 35S-methionine labeled K562 cell extracts. Clinical information of patients with this specificity was collected.Results: The 120 kD protein, which exactly comigrated with PL-12, was identified as transcription intermediary factor TIF1β (TRIM28) by mass spectrometry and validated by immunoassays. By immunofluorescence, anti-TIF1β positivity showed a fine-speckled nuclear staining pattern. Four cases of anti-TIF1β were identified; all are women, one each in a Japanese, African American, Caucasian, and Mexican individual. Three had a diagnosis of DM and one case was classified as having an undifferentiated connective tissue disease with an elevated CPK but without significant muscle symptoms. This individual also had a history of colon cancer, cervical squamous metaplasia and fibroid tumors of the uterus. Myopathy was mild in all cases and resolved without treatment in one case. The anti-TIF1β specificity was not found in other conditions.Conclusions: Anti-TIF1β is a new DM autoantibody associated with a mild form of myopathy. Whether it has an association with malignancy, as in the case of anti-TIF1γ, or other unique features will need to be evaluated in future studies.

Original languageEnglish
Article numberR79
JournalArthritis Research and Therapy
Volume14
Issue number2
DOIs
Publication statusPublished - Apr 18 2012

Fingerprint

Dermatomyositis
Autoantibodies
Transcription Factors
Leiomyoma
Muscular Diseases
Mass Spectrometry
Proteins
Myositis
Connective Tissue Diseases
K562 Cells
Metaplasia
Cell Extracts
Serum
Immunoassay
Immunoprecipitation
African Americans
Methionine
Colonic Neoplasms
Fluorescent Antibody Technique
transcriptional intermediary factor 1

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Satoh, M., Chan, J. Y. F., Ross, S. J., Li, Y., Yamasaki, Y., Yamada, H., ... Chan, E. K. L. (2012). Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis. Arthritis Research and Therapy, 14(2), [R79]. https://doi.org/10.1186/ar3802

Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis. / Satoh, Minoru; Chan, Jason Y F; Ross, Steven J.; Li, Yi; Yamasaki, Yoshioki; Yamada, Hidehiro; Mercado, Monica V Del; Petri, Marcelo H.; Jara, Luis J.; Saavedra, Miguel A.; Cruz-Reyes, Claudia; Sobel, Eric S.; Reeves, Westley H.; Ceribelli, Angela; Chan, Edward K L.

In: Arthritis Research and Therapy, Vol. 14, No. 2, R79, 18.04.2012.

Research output: Contribution to journalArticle

Satoh, M, Chan, JYF, Ross, SJ, Li, Y, Yamasaki, Y, Yamada, H, Mercado, MVD, Petri, MH, Jara, LJ, Saavedra, MA, Cruz-Reyes, C, Sobel, ES, Reeves, WH, Ceribelli, A & Chan, EKL 2012, 'Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis', Arthritis Research and Therapy, vol. 14, no. 2, R79. https://doi.org/10.1186/ar3802
Satoh, Minoru ; Chan, Jason Y F ; Ross, Steven J. ; Li, Yi ; Yamasaki, Yoshioki ; Yamada, Hidehiro ; Mercado, Monica V Del ; Petri, Marcelo H. ; Jara, Luis J. ; Saavedra, Miguel A. ; Cruz-Reyes, Claudia ; Sobel, Eric S. ; Reeves, Westley H. ; Ceribelli, Angela ; Chan, Edward K L. / Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis. In: Arthritis Research and Therapy. 2012 ; Vol. 14, No. 2.
@article{fdcf8ec2d70e41b9928ccc341ed6789d,
title = "Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis",
abstract = "Introduction: Myositis specific autoantibodies are associated with unique clinical subsets and are useful biomarkers in polymyositis/dermatomyositis (PM/DM). A 120 kD protein recognized by certain patients with DM was identified and clinical features of patients with this specificity were characterized.Methods: The 120 kD protein recognized by a prototype serum was purified and identified by mass spectrometry and immunological methods. Autoantibody to this 120 kD protein was screened in sera from 2,356 patients with various diagnoses from four countries, including 254 PM/DM, by immunoprecipitation of 35S-methionine labeled K562 cell extracts. Clinical information of patients with this specificity was collected.Results: The 120 kD protein, which exactly comigrated with PL-12, was identified as transcription intermediary factor TIF1β (TRIM28) by mass spectrometry and validated by immunoassays. By immunofluorescence, anti-TIF1β positivity showed a fine-speckled nuclear staining pattern. Four cases of anti-TIF1β were identified; all are women, one each in a Japanese, African American, Caucasian, and Mexican individual. Three had a diagnosis of DM and one case was classified as having an undifferentiated connective tissue disease with an elevated CPK but without significant muscle symptoms. This individual also had a history of colon cancer, cervical squamous metaplasia and fibroid tumors of the uterus. Myopathy was mild in all cases and resolved without treatment in one case. The anti-TIF1β specificity was not found in other conditions.Conclusions: Anti-TIF1β is a new DM autoantibody associated with a mild form of myopathy. Whether it has an association with malignancy, as in the case of anti-TIF1γ, or other unique features will need to be evaluated in future studies.",
author = "Minoru Satoh and Chan, {Jason Y F} and Ross, {Steven J.} and Yi Li and Yoshioki Yamasaki and Hidehiro Yamada and Mercado, {Monica V Del} and Petri, {Marcelo H.} and Jara, {Luis J.} and Saavedra, {Miguel A.} and Claudia Cruz-Reyes and Sobel, {Eric S.} and Reeves, {Westley H.} and Angela Ceribelli and Chan, {Edward K L}",
year = "2012",
month = "4",
day = "18",
doi = "10.1186/ar3802",
language = "English",
volume = "14",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis

AU - Satoh, Minoru

AU - Chan, Jason Y F

AU - Ross, Steven J.

AU - Li, Yi

AU - Yamasaki, Yoshioki

AU - Yamada, Hidehiro

AU - Mercado, Monica V Del

AU - Petri, Marcelo H.

AU - Jara, Luis J.

AU - Saavedra, Miguel A.

AU - Cruz-Reyes, Claudia

AU - Sobel, Eric S.

AU - Reeves, Westley H.

AU - Ceribelli, Angela

AU - Chan, Edward K L

PY - 2012/4/18

Y1 - 2012/4/18

N2 - Introduction: Myositis specific autoantibodies are associated with unique clinical subsets and are useful biomarkers in polymyositis/dermatomyositis (PM/DM). A 120 kD protein recognized by certain patients with DM was identified and clinical features of patients with this specificity were characterized.Methods: The 120 kD protein recognized by a prototype serum was purified and identified by mass spectrometry and immunological methods. Autoantibody to this 120 kD protein was screened in sera from 2,356 patients with various diagnoses from four countries, including 254 PM/DM, by immunoprecipitation of 35S-methionine labeled K562 cell extracts. Clinical information of patients with this specificity was collected.Results: The 120 kD protein, which exactly comigrated with PL-12, was identified as transcription intermediary factor TIF1β (TRIM28) by mass spectrometry and validated by immunoassays. By immunofluorescence, anti-TIF1β positivity showed a fine-speckled nuclear staining pattern. Four cases of anti-TIF1β were identified; all are women, one each in a Japanese, African American, Caucasian, and Mexican individual. Three had a diagnosis of DM and one case was classified as having an undifferentiated connective tissue disease with an elevated CPK but without significant muscle symptoms. This individual also had a history of colon cancer, cervical squamous metaplasia and fibroid tumors of the uterus. Myopathy was mild in all cases and resolved without treatment in one case. The anti-TIF1β specificity was not found in other conditions.Conclusions: Anti-TIF1β is a new DM autoantibody associated with a mild form of myopathy. Whether it has an association with malignancy, as in the case of anti-TIF1γ, or other unique features will need to be evaluated in future studies.

AB - Introduction: Myositis specific autoantibodies are associated with unique clinical subsets and are useful biomarkers in polymyositis/dermatomyositis (PM/DM). A 120 kD protein recognized by certain patients with DM was identified and clinical features of patients with this specificity were characterized.Methods: The 120 kD protein recognized by a prototype serum was purified and identified by mass spectrometry and immunological methods. Autoantibody to this 120 kD protein was screened in sera from 2,356 patients with various diagnoses from four countries, including 254 PM/DM, by immunoprecipitation of 35S-methionine labeled K562 cell extracts. Clinical information of patients with this specificity was collected.Results: The 120 kD protein, which exactly comigrated with PL-12, was identified as transcription intermediary factor TIF1β (TRIM28) by mass spectrometry and validated by immunoassays. By immunofluorescence, anti-TIF1β positivity showed a fine-speckled nuclear staining pattern. Four cases of anti-TIF1β were identified; all are women, one each in a Japanese, African American, Caucasian, and Mexican individual. Three had a diagnosis of DM and one case was classified as having an undifferentiated connective tissue disease with an elevated CPK but without significant muscle symptoms. This individual also had a history of colon cancer, cervical squamous metaplasia and fibroid tumors of the uterus. Myopathy was mild in all cases and resolved without treatment in one case. The anti-TIF1β specificity was not found in other conditions.Conclusions: Anti-TIF1β is a new DM autoantibody associated with a mild form of myopathy. Whether it has an association with malignancy, as in the case of anti-TIF1γ, or other unique features will need to be evaluated in future studies.

UR - http://www.scopus.com/inward/record.url?scp=84859791392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859791392&partnerID=8YFLogxK

U2 - 10.1186/ar3802

DO - 10.1186/ar3802

M3 - Article

VL - 14

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 2

M1 - R79

ER -